|Tested species reactivity||Human|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Extracellular fragment of recombinant human c-erbB-3/HER-3 oncoprotein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunoprecipitation (IP)||2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12867 targets HER-3 in FACS, IF, and IP applications and shows reactivity with Human samples.
The MA5-12867 immunogen is extracellular fragment of recombinant human c-erbB-3/HER-3 oncoprotein.
c-erbB-3/HER-3 is the third member of the type I family of growth factor receptors. It binds to ligands in the heregulin family. c-erbB-3 is over-expressed in a variety of tumors including breast, stomach, pancreas, and colon. Heregulin and EGF stimulate tyrosine phosphorylation of c-erbB-3 to different extents.
IP-MS enrichment of ERBB3 (LFQ intensity): ERBB3 was enriched 53-fold from MCF7 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ERBB3 antibody (Part No. MA5-12867). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
MA5-12867 was used in flow cytometry to develop and characterize specific antibodies targeting EGFR family
|Horak E,Heitner T,Robinson MK,Simmons HH,Garrison J,Russeva M,Furmanova P,Lou J,Zhou Y,Yuan QA,Weiner LM,Adams GP,Marks JD||Cancer biotherapy and radiopharmaceuticals (20:603)||2005|
Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
MA5-12867 was used in flow cytometry to compare ErbB2/beta-1 integrin/lipid raft interactions in cancer cells resistant and sensitive to Herceptin
|Mocanu MM,Fazekas Z,Petrás M,Nagy P,Sebestyén Z,Isola J,Tímár J,Park JW,Vereb G,Szöllosi J||Cancer letters (227:201)||2005|
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
MA5-12867 was used in flow cytometry to study the role of HER-2/neu overexpression in increasing the viable hypoxic cell population within solid tumors
|Dragowska WH,Warburton C,Yapp DT,Minchinton AI,Hu Y,Waterhouse DN,Gelmon K,Skov K,Woo J,Masin D,Huxham LA,Kyle AH,Bally MB||Molecular cancer research : MCR (2:606)||2004|
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
MA5-12867 was used in flow cytometry to study the role of alpha6beta1 integrin in inducing proteasome-mediated cleavage of erbB2 in breast cancer cells
|Shimizu H,Seiki T,Asada M,Yoshimatsu K,Koyama N||Oncogene (22:831)||2003|
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
MA5-12867 was used in flow cytometry to study the role of the HER-2 receptor in modulating the response of ovarian cancer cells to doxorubicin, cisplatin and taxol
|Aigner A,Hsieh SS,Malerczyk C,Czubayko F||Toxicology (144:221)||2000|
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
MA5-12867 was used in flow cytometry to investigate the synergistic inhibitory effect of anti-HER2 antibody and anti-oestrogen on breast cancer cells
|Kunisue H,Kurebayashi J,Otsuki T,Tang CK,Kurosumi M,Yamamoto S,Tanaka K,Doihara H,Shimizu N,Sonoo H||British journal of cancer (82:46)||2000|
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
MA5-12867 was used in flow cytometry to study the role of ErbB-4 in the proliferation of estrogen receptor-positive breast cancer cells
|Tang CK,Concepcion XZ,Milan M,Gong X,Montgomery E,Lippman ME||Cancer research (59:5315)||1999|
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
MA5-12867 was used in immunoprecipitation to investigate the interaction between HER-2 and HPV-16 in human mammary epithelial cells during malignant transformation
|Woods Ignatoski KM,Dziubinski ML,Ammerman C,Ethier SP||Neoplasia (New York, N.Y.) (7:788)||2005|
Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
MA5-12867 was used in immunohistochemistry to investigate the expression of heparin-binding epidermal growth factor-related factors and erbB receptors in normal and psoriatic keratinocytes
|Piepkorn M,Predd H,Underwood R,Cook P||Archives of dermatological research (295:93)||2003|
Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
MA5-12867 was used in western blot to study the molecular mechanisms by which heregulin regulates the reorganization of the actin cytoskeleton and cell migration
|Adam L,Vadlamudi R,Kondapaka SB,Chernoff J,Mendelsohn J,Kumar R||The Journal of biological chemistry (273:28238)||1998|
ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.
MA5-12867 was used in immunocytochemistry to investigate the effect of ErbB-4 ribozymes on neuregulin-induced mitogenesis
|Tang CK,Goldstein DJ,Payne J,Czubayko F,Alimandi M,Wang LM,Pierce JH,Lippman ME||Cancer research (58:3415)||1998|